About Cullinan Oncology
Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
Co-Founder and CSO: Patrick Baeuerle, PhD
CEO: Owen Hughes
CSO: Leigh Zawel, PhD
Please click here for Cullinan Oncology's approach.
5 articles with Cullinan Oncology
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics
Cullinan Oncology, LLC and MAB Discovery GmbH (MABD), announced today the initiation of a collaboration to develop novel antibody therapeutics based on MABD’s unique discovery platform.
The company announced today the appointment of Thomas Ebeling and Tony Rosenberg to its Board of Directors.
10/25/2017Rumor is there's a new approach to fighting cancer in town.